Lwimba Kasongo: ‘We Left No Stone Unturned’ – British Haematology Society and UK PACTS Train Local Health Workers
Lwimba Kasongo, Global Patient Advocate and Consultant at The University of Zambia, posted on LinkedIn:
”The British Haematology Society, with the UK PACTS program initiators and London medical Dr’s recently visited Zambia to train health workers on Sickle Cell Disease. This was conducted at two of our largest hospitals in separate provinces. Dr Sahar and Dr Telo were Zambia’s lead training Dr’s.
During the training, a patient panel was selected, Emmanuel and I spoke as SCD patient voices. We were brutally honest about the challenges we face: we left no stone unturned. Being labelled as drug addicts, insensitive comments, lack of urgency when managing our pain, the negligence and neglect in the ER and much more.
The look on their faces, as we spoke told one story, the harsh reality of SCD and how some of their attitudes and lack of knowledge have greatly contributed to increasing the burden of SCD on us.
On the bright side the objective of the training was achieved. Health personnel walked out fully equipped with knowledge on SCD and patient care
I first met the UK PACTS team 3 years ago through Prof. Baba and Dr Chunda – Liyoka. I’m so proud that their work remains truly patient-centered.”
Stay updated with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!